Anthony Stephen O'Brien - 04 May 2022 Form 4 Insider Report for Evofem Biosciences, Inc. (EVFM)

Reporting relationship: Director
Issuer ticker: EVFM
Reported as of: 04 May 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 06 May 2022, 16:10:43 UTC
Prior SEC filing: 14 Jun 2021
Source filing: View source filing
Reporting owner signature: /s/ Justin J. File, attorney-in-fact

Key filing fact

Anthony Stephen O'Brien filed Form 4 for Evofem Biosciences, Inc. (EVFM) on 06 May 2022.

Key facts

This page summarizes Anthony Stephen O'Brien's Form 4 filing for Evofem Biosciences, Inc. (EVFM).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 06 May 2022, 16:10.

Change

Previous filing in this sequence was filed on 14 Jun 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

EVFM transaction Derivative

Stock option (right to buy)

Award

Transaction value: $0
Shares: +6,000
Change %
Price: $0.000000
Shares after: 6,000
Date: 04 May 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 6,000
Exercise price: $2.47
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The figures reflected herein have been adjusted to take into account a 1 for 15 reverse split of the Company's common stock that was effected on May 5, 2022.

Footnote F2

The shares of common stock exercisable pursuant to the option will vest in full upon completion of continuous service for the Issuer on the first anniversary of the vesting commencement date of May 4, 2022. The option was awarded in connection with Mr. O'Brien's board and committee services.